Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its Category 1 product, GST-HG171/ritonavir, an oral COVID-19 therapy, has received conditional marketing approval in China. GST-HG171 is a 3CL protease (3CLpro) inhibitor, characterized as having broad-spectrum anti-COVID-19 activity.
3CL protease is an essential protease for the replication of COVID-19 and is highly conserved among coronaviruses. The likelihood of natural occurrence of non drug-induced mutations is low, and there is no human homologous protein, making it a safe target. Ritonavir, an oral anti-viral pharmacokinetic enhancer originally developed by AbbVie, is also included in the therapy.- Flcube.com
